| Literature DB >> 8537682 |
P W Berman1, K K Murthy, T Wrin, J C Vennari, E K Cobb, D J Eastman, M Champe, G R Nakamura, D Davison, M F Powell, J Bussiere, D P Francis, T Matthews, T J Gregory, J F Obijeski.
Abstract
Three chimpanzees immunized with recombinant gp120 from human immunodeficiency virus type 1 (HIV-1) strain MN and 1 control animal were challenged intravenously with a primary isolate of HIV-1SF2. Viral infection was detected in the control animal by viral culture, polymerase chain reaction, and multiple serologic assays beginning 2 weeks after infection. Markers of HIV-1 infection were not detected in any of the gp120-vaccinated animals during 12 months of follow-up. Antisera from the gp120-immunized chimpanzees were unable to neutralize the challenge virus cultured in peripheral blood mononuclear cells (PBMC). These studies demonstrate that immunization with recombinant gp120 derived from a T cell-adapted isolate prevented infection by a heterologous primary isolate of HIV-1. The results suggest that in vitro virus neutralization assays utilizing primary isolates cultured in PBMC may be imperfect indicators of protection in vivo.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8537682 DOI： 10.1093/infdis/173.1.52
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226